Case Challenges in HIV Medicine
Benefits, Barriers, & Best Practices in an Advancing Field
Meeting Slides
Clinical Practice Guidelines
Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.
Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Clin Infect Dis. 2014;58(1):e1-e34.
Recommendations for evaluation and management of bone disease in HIV.
Brown TT, Hoy J, Borderi M, et al. Clin Infect Dis. 2015;60(8):1242-1251.
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel.
Saag M, Gandhi R, Hoy J, et al. JAMA. 2020. [Epub ahead of print].
Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.
Stevens PE, Levin A. Ann Intern Med. 2013;158(11):825-830.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services
Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States.
US Department of Health and Human Services
Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy.
World Health Organization
Patient and Caregiver Resources
AIDSMap Resources
NAM Publications
Resources for persons living with HIV
Centers for Disease Control and Prevention
HIV resources
National Institutes of Health
Suggested Readings
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M, Orkin C, Podzamczer D, et al. Lancet HIV. 2019;6(9):e576-e587.
Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results.
Arribas JR, Thompson M, Sax PE, et al. J Acquir Immune Defic Syndr. 2017;75(2):211-218.
HIV and substance use disorder: role of the HIV physician.
Bositis CM, St. Louis J. Infect Dis Clin North Am. 2019;33(3):835-855.
Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States.
Colasanti J, Sumitani J, Mehta CC, et al. Open Forum Infect Dis. 2018;5(6):ofy104.
HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable.
Eisinger RW, Dieffenbach CW, Fauci AS. JAMA. 2019;321(5):451-452.
Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association.
Feinstein MJ, Hsue PY, Benjamin LA, et al. Circulation. 2019;140(2):e98-e124.
Linkage and antiretroviral therapy within 72 hours at a Federally Qualified Health Center in New Orleans.
Halperin J, Butler I, Connor K, et al. AIDS Patient Care STDS. 2018;32(2):39-41.
A care continuum of immediate ART for newly diagnosed patients and patients presenting later to care at a Federally Qualified Health Center in New Orleans.
Halperin J, Conner K, Butler I, et al. Open Forum Infect Dis. 2019;6(4):ofz161.
Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors.
Hoffmann C, Llibre JM. AIDS Rev. 2019;21(1):4-10.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid-initiation model of care for HIV-1 infection: primary analysis of the DIAMOND study.
Huhn GD, Crofoot G, Ramgopal M, et al. Clin Infect Dis. 2019. [Epub ahead of print]
Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment.
Lagathu C, Béréziat V, Gorwood J, et al. Expert Opin Drug Saf. 2019;18(9):829-840.
Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.
The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.
Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.
Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.
Sax PE, Erlandson KM, Lake JE, et al. Clin Infect Dis. 2020;71(6):1379-1389.
Current challenges and solutions in research and clinical care of older persons living with HIV: findings presented at the 9th International Workshop on HIV and Aging.
Sundermann EE, Erlandson KM, Pope CN, et al. AIDS Res Hum Retroviruses. 2019;35(11-12):985-998.
Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.
Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.
Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO Study.
van Wyk J, Ajana F, Bisshop F, et al. Clin Infect Dis. 2020. [Epub ahead of print].
Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana.
Zash R, Holmes L, Diseko M, et al. J Int AIDS Soc. 2020;23(suppl 4):183-184. Abstract OAXLB0102.
Interactive PresentationHIV From Then to Now: A Story of Resilience
This history of HIV details the incredible journey from HIV discovery, patient resilience, and early treatment in the 1980s and 1990s to our current standard of single-tablet regimens, rapid ART initiation, and HIV as a chronic disease
Benefits, Barriers, & Best Practices in an Advancing Field
Relevant Resources
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Practical Solutions Across the Spectrum of Care
